The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yes tkevin, the RF funding was relatively better for shareholders. And, if we had 2 further drawdowns left then why not utilise that before the NICE full recommendation in July? In my view, this indicates the BOD suspect it will not be confirmed as full in July.
I'm mindful that if investors don't buy in then Roger's prediction that the placing won't succeed becomes a kind of self-fulfilling prophecy but I can't bring myself to put more into this...fool me twice shame on me.
You'll recall from the investor presentation that even after his apology for if shareholders were misled , Cheek stated that another hospital would go live end of that week. Why has there been no news of that? Why is no none holding him to account for that? I'm afraid I can't trust anything this BOD say.
I agree with you about all those potentials JimiHendrix , which is why I will continue holding. However, as you also know we've been waiting for these potentials to come to fruition for years now. Further, the conduct of the BOD must make you question the company's attitude to delivering for shareholders.
Stockpick ,unless they were putting in serious money like many of us investors, it's clearly a way to protect their gravy train. Is there any plausible rational for the BOD knowing and stating there will be a placing, passing up many opportunities to place at a higher price, and then waiting till now to do it at over 50% discount?
What to do? if anything?
I’ve lost more than even you Roger! I had written it off in my head months ago so this hasn’t come as a blow.
Are any of you buying in at 1.5? I’m just not sure. In the past I though some of your posts were slightly too conspiratorial but you’ve been proved true. If the current SP is being artificially kept high by Peel then I’d lose even more.
With around 500M shares to get anywhere near my 38p average would need a MC of just under 200M! Not happening. However, another 15K at 1.5p would bring my average to under 19p. That seems more achievable, or at least I’d get most/more of my money back. I really can’t see any other way to make my losses back.
Perhaps I’m over thinking it but I just can’t fathom why the BOD would behave so reprehensibly. Unless they’re satan worshiping paedophiles why would they have shafted LTHs? The only rationale I can see is that they thought the confirmation of full recommendation for CYP219 would have happened by now or before the money ran out – but they could have got a bridging loan. I wonder if they’ve got wind that the recommendation will be conditional after all? If so, it’ll be around 2027 before GDR is viable.
In any case, to average down or not?
That's great advice Stockpickfree :
An emotional trader is a bad trader. It is not as it Cheek gives a feck or it will make any difference...
Give yourself some time to cool down before you make such a significant financial decision.
I had mentally written off my investment here months ago, but still hoped for the best.
That makes sense to me JimiHemdrix. It would be reasonable to take the RF drawdowns until confirmed full recommendation and then raise. I assume that GDR know if it’s confirmed as if anything untoward came up during the consultation they’d be approached to comment.
So, it could be great news. Or, it could be terrible news!
Thanks MyIPA. I think your analysis is spot on Roger. We just have to wait and find out which way things go.
Barring something significant and unforeseen the draft full recommendation ought to be confirmed. That really will be dramatic for GDR.
I noted Starres posted a subtle preemptive deramp in that even if it’s full recommendation it’ll be only when a lab test isn’t available, and that the NHS will provide more labs - as if the NHS can snap their fingers and a genomics lab would appear next to every hospital! No, there are only a handful of such labs in the country and they can’t cope with the limited testing at the moment. Time after time in the consultation when this lack of capacity was pointed out, NICE responded that the POC was the solution.
Confirmation on July 10th or sooner will be phenomenal for GDR, and of course once the platform is in wide use, all sorts of other tests can follow.
I’m quietly confident/hopeful. however, I’ve been wrong at every turn previously!
Yes Roger, not very good of Tiger to do that. Nevertheless, unfortunately there's not much to be optimistic about for us LTHs. Cheek is really cutting the funding announcement to the wire.
However, despite my skepticism the CYP2C19 got draft full approval. If this is confirmed in July, or before, things should look better. It's only two months away and I've been waiting over 4 years so far. I always thought AIHL would be our saviour; turns out it could be the clopidogrel test.
By the way Roger, and others, there were not 2 sales for 20K at 9:04am. That transaction was by Bed and ISA!
II sold 421,074 shares from my trading account and bought them back in my ISA account. I’m happy with the transaction as I feared I might lose more shares despite II’s reassurance.
Really goes to show that the classification of those buys and sells aren’t always correct.
Yes rbr08, CYP2C19 could be a lot bigger if it starts to get used for other indications as well as strokes. We had a clinician on this board who addressed this.
The potential is beyond doubt. As bighammer says, we just need to sort out the funding. It can't be too long now before we find out something.
Roger, I read all the available NICE consultation documents and I formed the view that things were not looking too positive for GDR due to the apparent lack of evidence on many issues. This was highlighted throughout the report by many commentators.
However, in full knowledge of all this, NICE have clearly given draft FULL recommendation. NICE didn't have to; they could have reserved judgement until the end of the consultation. The fact that they have given draft FULL recommendation suggests their view things differently and have different criteria - perhaps the POC and speed are overriding objectives.
Given the draft recommendation, it would be extraordinary to reverse the FULL recommendation unless something dramatic indeed occurs. That's obvious, otherwise NICE would have egg on their face. I don't think it's fair to state that GIno was being disingenuous.
Let's see if there's news on Friday, or whether we'll fave to wait to July. I have a feeling the raise and the FDA partnership deal are all riding on this event. GDR must be confident, otherwise why take it to the wire?